1-20 of 56
Andrew W. Roberts, MBBS, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 462.
https://doi.org/10.1182/blood-2019-126640
Published: 2019
Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 500.
https://doi.org/10.1182/blood-2019-125483
Published: 2019
Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Chloe Pek Sang Tang, MBBS, FRACP, Tamia Nguyen, Xing Zhou, Ella Thompson, PhD BSc, Hanzi Sun, Haimei Xing, Bo Zhang, Yin Guo, Lesley Ann Sutton, PhDBSc, Paolo Ghia, MD PhD, Richard Rosenquist, MD PhD, Lydia Scarfo, MD, Silvia Bonfiglio, John F. Seymour, MBBS, PhD FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, David C.S. Huang, MBBS MRCP PhD, Ye Liu, Chan Y. Cheah, David Alan Westerman, MBBS, FRCPA, FRACP, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS, MD, Piers Blombery, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 170.
https://doi.org/10.1182/blood-2019-125488
Published: 2019
Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 171.
https://doi.org/10.1182/blood-2019-125457
Published: 2019
Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3036.
https://doi.org/10.1182/blood-2019-126508
Published: 2019
Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3999.
https://doi.org/10.1182/blood-2019-126396
Published: 2019
Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej
Journal: Blood
Blood (2019) 134 (Supplement_1): 2791.
https://doi.org/10.1182/blood-2019-122974
Published: 2019
Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 756.
https://doi.org/10.1182/blood-2019-126619
Published: 2019
Journal Articles

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Meaghan Wall, MBBS, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4431.
https://doi.org/10.1182/blood-2018-99-113905
Published: 2018
Journal Articles

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Jianan Gong, PhD, Rachel Thijssen, Richard W Birkinshaw, PhD, Ella Thompson, PhD, Charis E Teh, PhD, Tamia Nguyen, Zhen Xu, PhD, Christoffer Flensburg, PhD, Thomas Lew, MBBS, Ian Majewski, PhD, Daniel Gray, David Alan Westerman, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, John F. Seymour, MBBS, PhD, Peter E Czabotar, PhD, David Huang, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): LBA-7.
https://doi.org/10.1182/blood-2018-120761
Published: 2018
Journal Articles

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Max Wolf, FRACP, FRCPA, MBBS, Surender Juneja, MD, David Alan Westerman, MBBS, FRCPA, FRACP, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1876.
https://doi.org/10.1182/blood-2018-99-114048
Published: 2018
Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD, Shuo Ma, MD PhD, Mary Ann Anderson, FRACP, FRCPA, MBBS, Michael Y. Choi, MD, Thomas J. Kipps, MD PhD, Kathryn Humphrey, Abdullah Masud, PhD, Ruby Nandam, RN, MSN, Su Young Kim, MD PhD, Maria E. Verdugo, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 183.
https://doi.org/10.1182/blood-2018-183
Published: 2018
Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 333.
https://doi.org/10.1182/blood-2018-99-114243
Published: 2018
Journal Articles

Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

Donia M Moujalled, PhD, Diane T Hanna, Giovanna Pomilio, Veronique Litalien, Shaun Fleming, Marie Chanrion, Ana-Leticia Maragno, Laurence Kraus-Berthier, Seong Lin Khaw, Guillaume Lessene, David Huang, Andrew W. Roberts, MBBS, PhD, Olivier Geneste, Paul G Ekert, Ashley P Ng, Andrew H Wei, MBBS,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 567.
https://doi.org/10.1182/blood-2018-99-114051
Published: 2018
Journal Articles

Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy

Matthew S. Davids, MD, Andrew W. Roberts, MBBS, PhD, William G. Wierda, MD PhD, Kathryn Humphrey, Debbie J Alter, RN, BSN, Abdullah Masud, PhD, Eike C. Buss, MD, Maria E. Verdugo, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2883.
https://doi.org/10.1182/blood-2018-99-117210
Published: 2018
Journal Articles

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G. Wierda, MD PhD, Andrew W. Roberts, MBBS, PhD, Paolo Ghia, MD PhD, Jennifer R. Brown, MD PhD, Stephan Stilgenbauer, Florence Cymbalista, MD, Nicole Lamanna, MD, John F. Seymour, MBBS, PhD, Sebastian Böttcher, MD, Madlaina Breuleux, PhD DAS, Brenda Chyla, Lang Zhou, PhD, Jacqueline Nielsen, PhD, Su Young Kim, MD PhD, Jalaja Potluri, MD, Johnathan C. Maher, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 3134.
https://doi.org/10.1182/blood-2018-99-110183
Published: 2018
Journal Articles

The Role of BAX/BAK-Mediated Apoptosis for the Cytotoxic Action of Anti-Myeloma Agents

Yuan Yao, Jia-Nan Gong, PhD, David Segal, PhD, Chris D Riffkin, Mark F van Delft, PhD, Andrew W. Roberts, MBBS, PhD, David CS Huang, MBBS, MRCP, PhD
Journal: Blood
Blood (2016) 128 (22): 5706.
https://doi.org/10.1182/blood.V128.22.5706.5706
Published: 2016
Journal Articles

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Thomas E Lew, Mary Ann Anderson, MBBS, Constantine S. Tam, MBBS, David C.S. Huang, MBBS, MRCP, PhD, Surender Juneja, MD FRCPA, David A Westerman, MBBS, FRACP, FRCPA, John F Seymour, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 3223.
https://doi.org/10.1182/blood.V128.22.3223.3223
Published: 2016
Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD
Journal: Blood
Blood (2016) 128 (22): 338.
https://doi.org/10.1182/blood.V128.22.338.338
Published: 2016
Journal Articles

Targeting the Pro-Survival BCL2 Proteins with BH3 Mimetic Compounds for Treating Multiple Myeloma

Jia-Nan Gong, PhD, Tiffany Khong, PhD, David Segal, PhD, Yuan Yao, Mark F van Delft, PhD, Andrew Spencer, Andrew W Roberts, MBBS, PhD, David CS Huang, MBBS, MRCP, PhD
Journal: Blood
Blood (2016) 128 (22): 3293.
https://doi.org/10.1182/blood.V128.22.3293.3293
Published: 2016